Pur-Ther
@pur-ther.bsky.social
New immunotherapies targeting the key purinergic checkpoints in the tumor microenvironment
Amazing publication from the THUNDER lab at UKE, which is also part of our consortium!
It's about a new class of engagers for the treatment of multiple myeloma.🧑🔬🤯🤩 #sciencerocks #CD38 #nanobody
www.nature.com/articles/s41...
It's about a new class of engagers for the treatment of multiple myeloma.🧑🔬🤯🤩 #sciencerocks #CD38 #nanobody
www.nature.com/articles/s41...
CD38-specific nanobody-based bispecific antibody recruiters (BARs) redirect complement-dependent cytotoxicity toward multiple myeloma cells - Scientific Reports
Bispecific antibody recruiters (BARs) are an innovative class of immunotherapeutics that redirect endogenous antibodies to tumor cells. BARs comprise a tumor-binding and an antibody-binding module, en...
www.nature.com
January 15, 2026 at 1:59 PM
Amazing publication from the THUNDER lab at UKE, which is also part of our consortium!
It's about a new class of engagers for the treatment of multiple myeloma.🧑🔬🤯🤩 #sciencerocks #CD38 #nanobody
www.nature.com/articles/s41...
It's about a new class of engagers for the treatment of multiple myeloma.🧑🔬🤯🤩 #sciencerocks #CD38 #nanobody
www.nature.com/articles/s41...
🚨 New Publication Alert! 🚨
Long-Mira et al. explore the role of CD73 in EGFR-mutated lung adenocarcinoma.
We’re proud to share that one of the co-authors, Valerie Vouret-Craviari, is a member of our consortium! 🌟
www.mdpi.com/2072-6694/17...
Long-Mira et al. explore the role of CD73 in EGFR-mutated lung adenocarcinoma.
We’re proud to share that one of the co-authors, Valerie Vouret-Craviari, is a member of our consortium! 🌟
www.mdpi.com/2072-6694/17...
www.mdpi.com
March 24, 2025 at 12:38 PM
🚨 New Publication Alert! 🚨
Long-Mira et al. explore the role of CD73 in EGFR-mutated lung adenocarcinoma.
We’re proud to share that one of the co-authors, Valerie Vouret-Craviari, is a member of our consortium! 🌟
www.mdpi.com/2072-6694/17...
Long-Mira et al. explore the role of CD73 in EGFR-mutated lung adenocarcinoma.
We’re proud to share that one of the co-authors, Valerie Vouret-Craviari, is a member of our consortium! 🌟
www.mdpi.com/2072-6694/17...
Within Pur-Ther, we are looking into purinergic checkpoints like P2X7, CD73, and CD39, and their role in the tumor microenvironment.
Stay tuned for insights and discoveries shaping the future of immunotherapies! 🌟 🧑🔬 👨🔬 ⚗️
#PurinergicSignaling #P2X7 #ATP #Immunotherapy #TRANSCAN
Stay tuned for insights and discoveries shaping the future of immunotherapies! 🌟 🧑🔬 👨🔬 ⚗️
#PurinergicSignaling #P2X7 #ATP #Immunotherapy #TRANSCAN
February 11, 2025 at 11:32 AM
Within Pur-Ther, we are looking into purinergic checkpoints like P2X7, CD73, and CD39, and their role in the tumor microenvironment.
Stay tuned for insights and discoveries shaping the future of immunotherapies! 🌟 🧑🔬 👨🔬 ⚗️
#PurinergicSignaling #P2X7 #ATP #Immunotherapy #TRANSCAN
Stay tuned for insights and discoveries shaping the future of immunotherapies! 🌟 🧑🔬 👨🔬 ⚗️
#PurinergicSignaling #P2X7 #ATP #Immunotherapy #TRANSCAN